Forte Biosciences (FBRX) Cash from Operations (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Cash from Operations data on file, last reported at 18800000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 81.55% year-over-year to 18800000.0 in Q1 2026; TTM through Mar 2026 was 59345000.0, a 72.35% decrease from a year earlier, with the FY2025 full-year figure at 50900000.0, down 65.56% from the prior year.
• Cash from Operations for Q1 2026 stood at 18800000.0, down from 16484000.0 in the prior quarter.
• Over the last five years, Cash from Operations for FBRX reached as high as 1377000.0 in Q2 2022 and fell as low as 18800000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 8078588.24 across 5 years, with a median of 8133000.0 in 2024.
• Across the five-year window, Cash from Operations soared 65.03% in 2022 and plunged 366.91% in 2023, its largest moves.
• Year by year, Cash from Operations stood at 2893000.0 in 2022, then slumped by 210.02% to 8969000.0 in 2023, then dropped by 11.6% to 10009000.0 in 2024, then plunged by 64.69% to 16484000.0 in 2025, then fell by 14.05% to 18800000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 18800000.0 in Q1 2026, 16484000.0 in Q4 2025, and 14000000.0 in Q3 2025.